{"organizations": [], "uuid": "6ab7d58bdbdafde623434b374b9be9c92ffe4e3b", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/02/07/business-wire-vizient-inc-joins-other-health-care-leaders-to-support-the-creates-act.html", "country": "US", "domain_rank": 767, "title": "Vizient, Inc. Joins Other Health Care Leaders to Support the CREATES Act", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.059, "site_type": "news", "published": "2018-02-07T19:01:00.000+02:00", "replies_count": 0, "uuid": "6ab7d58bdbdafde623434b374b9be9c92ffe4e3b"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/02/07/business-wire-vizient-inc-joins-other-health-care-leaders-to-support-the-creates-act.html", "ord_in_thread": 0, "title": "Vizient, Inc. Joins Other Health Care Leaders to Support the CREATES Act", "locations": [], "entities": {"persons": [{"name": "dan kistner", "sentiment": "none"}], "locations": [{"name": "texas", "sentiment": "none"}, {"name": "irving", "sentiment": "none"}], "organizations": [{"name": "vizient, inc", "sentiment": "neutral"}, {"name": "congress", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "IRVING, Texas--(BUSINESS WIRE)-- Vizient, Inc ., joins more than 40 other health care leaders to voice its strong support for the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act (S. 974/H.R. 2212).\nThe CREATES Act addresses delay tactics used by brand manufacturers to block entry of generic drugs into the marketplace by allowing generic manufacturers to obtain relief for the delay tactics being used to prevent their entry.\n“We strongly encourage Congress to pass this critical legislation as soon as possible,” said Dan Kistner, senior vice president, Vizient pharmacy solutions. “The CREATES Act will help improve access and affordability for the health care providers we serve, and in turn that helps them fulfill their mission to provide the best possible care to their patients and communities.”\nVizient is the nation’s largest health care performance improvement company serving a diverse membership that includes academic medical centers, pediatric facilities, community hospitals, integrated health care delivery networks and non-acute health care providers.\nAbout Vizient, Inc.\nVizient, Inc., the largest member-driven health care performance improvement company in the country, provides innovative data-driven solutions, expertise and collaborative opportunities that lead to improved patient outcomes and lower costs. Vizient’s diverse membership base includes academic medical centers, pediatric facilities, community hospitals, integrated health delivery networks and non-acute health care providers and represents more than $100 billion in annual purchasing volume. The Vizient brand identity represents the integration of VHA Inc., University HealthSystem Consortium and Novation, which combined in 2015, as well as MedAssets’ Spend and Clinical Resource Management (SCM) segment, including Sg2, which was acquired in 2016. In 2017, Vizient again received a World’s Most Ethical Company designation from the Ethisphere Institute. Vizient’s headquarters are in Irving, Texas, with locations in Chicago and other cities across the United States. Please visit www.vizientinc.com as well as our newsroom , blog , Twitter , LinkedIn and YouTube pages for more information about the company.\nView source version on businesswire.com : http://www.businesswire.com/news/home/20180207005842/en/\nVizient, Inc.\nAngie Boliver, 972-830-7961\nangie.boliver@vizientinc.com\nSource: Vizient, Inc.", "external_links": ["http://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Ftwitter.com%2FVizientInc&esheet=51755024&newsitemid=20180207005842&lan=en-US&anchor=Twitter&index=6&md5=4e15e7a44b317a82d7dd8e6b1b0fa9d7", "http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fnewsroom.vizientinc.com%2Fblog&esheet=51755024&newsitemid=20180207005842&lan=en-US&anchor=blog&index=5&md5=da62d04fdf05a4d547e673e0c0f72080", "http://www.businesswire.com/news/home/20180207005842/en/", "http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.csrxp.org%2Fwp-content%2Fuploads%2F2018%2F02%2FCREATES-Act-Letter-2.6.18.pdf&esheet=51755024&newsitemid=20180207005842&lan=en-US&anchor=support&index=2&md5=272548687a02896ba987a1e55fe26a06", "http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fnewsroom.vizientinc.com%2F&esheet=51755024&newsitemid=20180207005842&lan=en-US&anchor=newsroom&index=4&md5=912dee1f6250ebe8586576afe5b77860", "http://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.youtube.com%2Fchannel%2FUC5a6JN4fky12DDuNUVTcm7g&esheet=51755024&newsitemid=20180207005842&lan=en-US&anchor=YouTube&index=8&md5=26831726b74ffd42247bd33cb28516ef", "http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.vizientinc.com&esheet=51755024&newsitemid=20180207005842&lan=en-US&anchor=Vizient%2C+Inc&index=1&md5=1db83b9e0f4d31d0d46d4fabc37a4b82", "http://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fvizient&esheet=51755024&newsitemid=20180207005842&lan=en-US&anchor=LinkedIn&index=7&md5=0b4eb3122edf86e68951c5d99aaf6f52", "http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.vizientinc.com&esheet=51755024&newsitemid=20180207005842&lan=en-US&anchor=www.vizientinc.com&index=3&md5=7cab2203c1955039654ce5a626f0bcf7"], "published": "2018-02-07T19:01:00.000+02:00", "crawled": "2018-02-07T19:53:02.004+02:00", "highlightTitle": ""}